Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 2

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
In Pakistan the Siwalik region is exposed to ionizing radiation (IR) from uranium mineralization. The current research describes the impact of long-term low-dose terrestrial ionizing radiation exposure on the hematopoietic indices of the region’s inhabitants. Mean values of the selected complete blood count (CBC) parameters were calculated to examine low or high trend. A t-test was conducted on the mean values of CBC parameters to analyze parameters showing a significant difference between radiation-exposed people and radiation unexposed people. Most disturbed CBC parameters found low were: mean corpuscular hemoglobin (MCH) 52%, mean corpuscular hemoglobin concentration (MCHC) 44%, and platelets (PLT) 28%. The most affected CBC parameter which was found to be high was lymphocyte count (LYM) 28%. Seven CBC parameters, including hemoglobin (HB), white blood cells (WBC), platelets (PLT), hematocrit (HCT), neutrophils (NEUT), MCH, and MCHC, showed a decrease trend in radiation-exposed residents and two CBC parameters, including red blood cells (RBC) and LYM, showed an increased trend. Significant differences were found in the parameters viz., HB, WBC, MCH, MCHC, HCT, and LYM by the t-test between radiation exposed and unexposed individuals. The odds of developing a low MCH were four times higher and the odds of developing a low MCHC were 4.4 times higher for radiation-exposed individuals as compared to radiation unexposed. The persistent low-dose IR exposure resulted in anemia and immune modulation in radiation-exposed residents.
Endoxifen, an active metabolite of tamoxifen, has been shown to be an effective anti-estrogenic agent in estrogen receptor-positive breast cancer patients. In melanoma, estrogen receptor expression is shown to be associated with disease progression. However, the therapeutic benefit of endoxifen in melanoma has not yet been evaluated. Here, we present the first demonstration of the anti-melanogenic activity of endoxifen in vitro and in vivo. The in vitro cytotoxic effect of endoxifen was tested using a cell viability assay. The in vivo anti-melanogenic activity was evaluated in B16F10 cell-bearing C57BL/6 mice, a mouse melanoma model. The general toxicity was tested in Swiss albino mice. Endoxifen exhibited greater activity against melanoma cell lines. Treatment of B16F10 mouse and SK-MEL-5 human melanoma cell lines with 10 μM of endoxifen for 48 h respectively resulted in 93.6 and 92.5% cell death. Orally administered endoxifen, at dose levels of 4 and 8 mg/kg body weight/day for 20 consecutive days, respectively reduced metastatic melanoma nodules in the lungs by 26.7 and 82.7%. Endoxifen was found to be a safe and effective anti-melanogenic agent in animal studies.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.